Atalan Capital Partners LP Has $123.22 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Atalan Capital Partners LP decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 520,000 shares of the medical research company’s stock after selling 35,000 shares during the period. IQVIA comprises 10.6% of Atalan Capital Partners LP’s portfolio, making the stock its 6th biggest position. Atalan Capital Partners LP’s holdings in IQVIA were worth $123,224,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. First Foundation Advisors increased its position in shares of IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares during the last quarter. Invera Wealth Advisors LLC increased its holdings in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after buying an additional 46 shares during the last quarter. Private Trust Co. NA raised its position in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its stake in IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after acquiring an additional 48 shares during the last quarter. Finally, Continuum Advisory LLC increased its stake in shares of IQVIA by 3.3% during the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after purchasing an additional 49 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IQV has been the subject of a number of research analyst reports. TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Truist Financial decreased their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Evercore ISI dropped their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. decreased their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Down 0.3 %

IQV stock opened at $200.84 on Monday. The stock has a market capitalization of $36.45 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a 50-day moving average price of $218.67 and a 200-day moving average price of $226.11. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.